Effects of nebulized bronchodilator therapy on heart rate and arrhythmias in critically ill adult patients

Chest

Volumn 140, Issue 6, 2011, Pages 1466-1472

  Khorfan, Fahim M ^a,b   Smith, Patricia ^a   Watt, Sandra ^a   Barber, Kimberly R ^a,b  

^a GENESYS REGIONAL MEDICAL CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; LEVALBUTEROL; SALBUTAMOL;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TELEMETRY;

EID: 83455201130     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0525     Document Type: Article

References (46)

1. Kleiger RE, Senior RM. Longterm electrocardiographic monitoring of ambulatory patients with chronic airway obstruction . Chest. 1974;65(5):483-487.
2. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21(6):1012-1016. (Pubitemid 36675619)
3. Shih HT, Webb CR, Conway WA, Peterson E, Tilley B, Goldstein S. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest. 1988;94(1) : 44-48.
4. Fuso L, Incalzi RA, Pistelli R, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med. 1995;98(3):272-277.
5. Hudson LD, Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest. 1973;63(5):661-665.
6. Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore). 2008;87(6):319-328.
7. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J. 1998;19(suppl F) : F14-F18. (Pubitemid 28266403)
8. Kallergis EM, Manios EG, Kanoupakis EM, et al. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest. 2005;127(6):2057-2063.
9. Kiely DG, Cargill RI, Grove A, Struthers AD, Lipworth BJ. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax. 1995;50(10):1062-1066.
10. Cekici L, Valipour A, Kohansal R, Burghuber OC. Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study. Br J Clin Pharmacol. 2009;67(4):394-402.
11. Kaya D, Barutcu I, Esen AM, Onrat E, Orman A, Unlu M. Comparison of the effects of ipratropium bromide and salbutamol on autonomic heart rate control. Europace. 2004; 6(6):602-607. (Pubitemid 40378705)
12. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137(1):13-19.
13. Schulz KF, Altman DG, Moher D;CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Ann Int Med. 2010; 152(11):726-732.
14. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S; Dey Combination Solution Study Group. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration. 1998; 65(5):354-362. (Pubitemid 28491270)
15. Jouven X, Zureik M, Desnos M, Guérot C, Ducimetière P. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res. 2001;50(2):373-378. (Pubitemid 32382164)
16. Berton GS, Cordiano R, Palmieri R, Gheno G, Mormino P, Palatini P. Heart rate during myocardial infarction: relationship with one-year global mortality in men and women. Can J Cardiol. 2002;18(5):495-502. (Pubitemid 34784832)
17. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy . Am J Med. 2003;114(1):51-55. (Pubitemid 36126516)
18. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004;26(7-8) : 637-644. (Pubitemid 40129752)
19. Robin ED, McCauley R. Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. Chest. 1992; 101(6):1699-1702.
20. Costello J. Cardiac effects of beta-agonists in patients with COPD. Chest. 1998;114(2):353-354. (Pubitemid 28387503)
21. Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med. 1996; 154(6 pt 1):1598-1602. (Pubitemid 26424921)
22. Duane M, Chandran L, Morelli PJ. Recurrent supraventricular tachycardia as a complication of nebulized albuterol treatment. Clin Pediatr (Phila). 2000;39(11):673-677.
23. Keller KA, Bhisitkul DM. Supraventricular tachycardia: a complication of nebulized albuterol. Pediatr Emerg Care.1995;11(2):98-99.
24. Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis. 1988;138(4):850-855.
25. Yuksel H, Coskun S, Polat M, Onag A. Lower arrythmogenic risk of low dose albuterol plus ipratropium. Indian J Pediatr.2001;68(10):945-949. (Pubitemid 33097975)
26. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-2321. (Pubitemid 38796452)
27. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA;Levalbuterol Pediatric Study Group. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol. 2001;108(6):938-945. (Pubitemid 33151546)
28. Chowdhury BA, Dal Pan GD. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010;362(13):1169-1171.
29. Sears MR. Safety of long-acting beta-agonists: are new data really required? Chest. 2009;136(2):604-607.
30. Taylor DR. The beta-agonist saga and its clinical relevance: on and on it goes. Am J Respir Crit Care Med. 2009;179(11) : 976-978.
31. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med. 2009;360(16) : 1670-1671.
32. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of longacting beta-agonsists in stable COPD: a systematic review. Chest. 2008;133(5):1079- 1087. (Pubitemid 351685509)
33. Sears MR. Long-acting bronchodilators in COPD. Chest.2008;133(5):1057- 1058. (Pubitemid 351685502)
34. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med. 2005; 353 (25): 2637- 2639.
35. Andrade Capuchinho-Júnior G, Marques Dias R, Regina da Silva de Carvalho S. One hour effects of salbutamol and formoterol on blood pressure, heart rate and oxygen saturation in asthmatics. Rev Port Pneumol. 2008;14(3):353-361.
36. Braun SR, Levy SF, Grossman J. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med. 1991;91(4 suppl 1) : S 28 -S 32.
37. Lee H, Evans HE. Lack of cardiac effect from repeated doses of albuterol aerosol. A margin of safety. Clin Pediatr (Phila).1986;25(7):349-352. (Pubitemid 16065787)
38. Suissa S, Assimes T, Ernst P. Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax. 2003;58(1):43-46. (Pubitemid 36135357)
39. Page CP, Morley J. Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol. 1999;104(2 pt 2) : S31-S41. (Pubitemid 29426707)
40. Rau JL. Introduction of a single isomer beta agonist. Respir Care. 2000;45(8):962-966.
41. Dhand R, Goode M, Reid R, Fink JB, Fahey PJ, Tobin MJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med. 1999;160(4):1136-1141. (Pubitemid 29487451)
42. Ameredes BT, Calhoun WJ. (R)-albuterol for asthma: pro [a.k.a. (S)-albuterol for asthma: con]. Am J Respir Crit Care Med. 2006;174(9):965-969.
43. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol. 1999;103(4):615-621. (Pubitemid 29295567)
44. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998;102(6 pt 1):943-952. (Pubitemid 29018311)
45. Scott VL, Frazee LA. Retrospective comparison of nebulized levalbuterol and albuterol for adverse events in patients with acute airflow obstruction. Am J Ther. 2003;10(5):341-347.
46. Lam S, Chen J. Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients. Am J Health Syst Pharm. 2003;60(19):1971-1975. (Pubitemid 44712895)